Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for @entity1103 in XXXX : subgroup analysis of a retrospective chart review study.

@entity1 @entity9170 @entity2994 @entity1103 @entity2790
BACKGROUND: Dexamethasone intravitreal implant ( @entity9170 implant) is a sustained-release biodegradable implant approved for treatment of @entity1103 associated with @entity2994 ( @entity2994 ). The safety and efficacy of treatment of @entity2994 -associated @entity1103 with sequential @entity9170 implants in clinical practice was evaluated in @entity1 who received @entity9170 implant as monotherapy compared with @entity1 who received @entity9170 implant in combination with other @entity2994 treatments. METHODS: A multicenter, retrospective, open-label chart review study (one study eye/ @entity1 ) evaluated use of @entity9170 implant and outcomes in 289 @entity1 with branch or central @entity2994 who received at least 2 @entity9170 implant treatments in the study eye. Data were collected from the time of the first implant (baseline) to 3-6 months after the last implant. Subgroup analysis evaluated outcomes in @entity1 receiving only @entity9170 implant during the study versus @entity1 receiving @entity9170 implant plus adjunctive @entity2994 treatments. Endpoints included best-corrected visual acuity (BCVA) and central retinal thickness (CRT) change from baseline. RESULTS: @entity9170 implant was used as monotherapy in 84 (29.1%) @entity1 and in combination with other therapy in 205 (70.9%) @entity1 . Mean number of @entity9170 implant treatments received was 3.1 in the monotherapy group and 3.3 in the combination therapy group (P   =   0.344). Mean time between implants was longer in the combination therapy group (177 vs. 151  days, P   <   0.001). Mean change from baseline BCVA after the first through sixth @entity9170 implants ranged from +0.6 to +3.4 lines in the monotherapy group and +1.3 to +2.8 lines in the combination therapy group. Mean decrease from baseline CRT ranged from 165 to 230   m in the monotherapy group and 136 to 175   m in the combination therapy group. @entity2790 was more common in the combination therapy group. CONCLUSIONS: Treatment of @entity2994 -associated @entity1103 with at least 2 sequential @entity9170 implants was safe and effective both when used alone and when combined with other @entity2994 treatments. Improvements in BCVA and CRT were generally similar in the monotherapy and combined therapy groups. TRIAL REGISTRATION: ClinicalTrials.gov NCT01411696 .
